Onkológia 1/2019
Gastrointesintal stromal tumors – new possibilities in the strategy of treatment
Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor in the gastrointestinal tract. This is a rare tumor with an incidence of approximately 1/100,000 / year. The major molecular marker is KIT protein - tyrosine kinase receptor (CKIT or CD117), which is expressed in 95% of GIST and 80% mutant patients. The treatment is based on radical resection. Patients with moderate to high risk should be given a 3-year adjuvant with imatinib. In case of progression / recurrence of the disease, it is possible to use imatinib, sunitinib or regorafenib. New molecules are being studied and their need is mainly in resistant diseases for standard therapy.
Keywords: gastrointestinal stromal tumor, imatinib, sunitinib, regorafenib












